Umbilical Cord-derived Mesenchymal Stem Cells for Ischemic Stroke
Launched by GENERAL HOSPITAL OF SHENYANG MILITARY REGION · Mar 19, 2021
Trial Information
Current as of July 09, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age: 18-80 years old;
- • 2. Patients with anterior circulation cerebral infarction;
- • 3. NIHSS: 6-25, and the limb movement score is at least 2 points;
- • 4. Hemoglobin \> 115g / L, platelet \> 100 × 109 / L, leukocyte \> 3 × 109 / L;
- • 5. the time from onset to treatment: group A(6-24 hours)、group B(1-3 days)、gourp C(4-7 days)、group D(1-4 weeks)、group E(1-6 months);
- • 6. The patient or the legal representative of the patient can and is willing to sign the informed consent.
- Exclusion Criteria:
- • 1. Patients who need or expect decompressive craniectomy;
- • 2. Patients who need or are expected to receive endovascular treatment ;
- • 3. Patients receiving intravenous thrombolysis;
- • 4. Disturbance of consciousness;
- • 5. Pregnant women or women of childbearing age who have not taken effective contraceptive measures;
- • 6. Intracranial hemorrhagic diseases: cerebral hemorrhage, subarachnoid hemorrhage, etc;
- • 7. Posterior circulation cerebral infarction;
- • 8. Tumor patients;
- • 9. Epilepsy patients;
- • 10. Severe neurological deficit caused by stroke (MRS = 5);
- • 11. Previous diseases with obvious functional impairment, such as Parkinson's disease, motor neuron disease, moderate Alzheimer's disease, osteoarthritis, etc;
- • 12. Patients with history of coagulation disorders, systemic bleeding tendency and thrombocytopenia (\< 100000 / mm3);
- • 13. Chronic liver disease, liver and kidney dysfunction, elevated ALT or ast (2 times higher than the upper limit of normal value), elevated serum creatinine (1.5 times higher than the upper limit of normal value) or dependent on renal dialysis;
- • 14. Patients with moderate to severe mental illness obviously interfere with treatment compliance;
- • 15. Patients with high blood pressure (systolic blood pressure \> 180mmhg) or low blood pressure (systolic blood pressure \< 90mmHg);
- • 16. The expected survival time is less than one year;
- • 17. Those who have conducted other trials within 3 months;
- • 18. Other circumstances considered unsuitable by the researcher.
About General Hospital Of Shenyang Military Region
The General Hospital of Shenyang Military Region is a leading medical institution in China, dedicated to advancing healthcare through innovative clinical research and trials. As a prominent sponsor of clinical studies, the hospital leverages its extensive resources and expertise to explore new therapeutic interventions and improve patient outcomes. Committed to upholding the highest ethical standards and regulatory compliance, the hospital fosters collaboration among multidisciplinary teams to drive scientific discovery and enhance the quality of care within military and civilian populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shenyang, , China
Patients applied
Trial Officials
Chen Hui-Sheng, Doctor
Principal Investigator
General Hospital of Shenyang Military Region
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials